Novel MLL-CBP fusion transcript in therapy-related chronic myelomonocytic leukemia with a t(11;16) (q23;p13) chromosome translocation

✍ Scribed by Noriko Satake; Yasushi Ishida; Yoshiko Otoh; Shin-ichi Hinohara; Hirofumi Kobayashi; Akiko Sakashita; Nobuo Maseki; Yasuhiko Kaneko

• Publisher: John Wiley and Sons
• Year: 1997
• Tongue: English
• Weight: 58 KB
• Volume: 20
• Category: Article
• ISSN: 1045-2257
• DOI: 10.1002/(sici)1098-2264(199709)20:1<60::aid-gcc9>3.0.co;2-7

✦ Synopsis

CBP, which is located on 16p13 and encodes a transcriptional adaptor/coactivator protein, has been shown to fuse by the t(8;16)(p11;p13) translocation to MOZ on 8p11 in acute myeloid leukemia. We found a t(11;16)(q23;p13) in a child with therapy-related chronic myelomonocytic leukemia. Subsequent reverse transcriptase-polymerase chain reaction and direct sequencing analyses revealed the MLL-CBP fusion transcript in CMML cells. Because 11q23 translocations involving MLL and t(8;16) involving MOZ and CBP have been reported in therapy-related leukemias, both the MLL and CBP genes may be targets for topoisomerase II inhibitors. Accordingly, we believe that most t(11;16)-associated leukemias may develop in patients who have been treated with cytotoxic chemotherapy for primary malignant diseases.